# US 2014/0194318 A1 · Biomarkers for diagnosing alzheimer's disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194318 A1 - Document ID: US20140194318A1 - Status: Published application - Kind: A1 - Application number: 14/217,716 - Filed: 2014-03-18 - Published: 2014-07-10 - Earliest claimed: 2002-08-23 - Assignees: Bayer Intellectual Property GmbH - Applicants: Bayer Intellectual Property GmbH - Inventors: Õzkan Yalkinoglu; Gerhard König; Denis F. Hochstrasser; Jean-Charles Sanchez; Odile Carrette - Web page: https://patentgrep.com/patent/US20140194318A1 ## CPC - G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease} - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - C07K 14/805: Haemoglobins; Myoglobins - C07K 14/8139: {Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin} - G01N 2800/2821: Alzheimer - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis. ## Claims ### Claim 1 (canceled) ### Claim 2 An isolated polypeptide having the amino acid sequence of SEQ ID NO: 17. ### Claim 3 A method for assessing the state of Alzheimer's disease in a subject, wherein the method comprises detecting in a sample from the subject at least one polypeptide from each of the following groups: a) a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16; b) a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 4, 5, and 6; and c) a polypeptide having the amino acid sequence of SEQ ID NO: 17. ### Claim 4 (depends on 3) The method of claim 3, wherein the method further comprises contacting the sample with an antibody that specifically binds one of the polypeptides. ### Claim 5 (depends on 3) The method of claim 3, wherein at least one polypeptide is detected by SELDI-TOF MS. ### Claim 6 (depends on 3) The method of claim 3, wherein the method is performed on at least two samples from the subject. ### Claim 7 (depends on 3) The method of claim 3, wherein the sample is CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, or cell extract. ### Claim 8 (depends on 3) The method of claim 3, wherein the polypeptides are detected in one sample from the subject. ### Claim 9 A method for assessing the state of Alzheimer's disease in a subject, wherein the method comprises detecting in a sample from the subject at least three distinct polypeptides, wherein a first polypeptide is selected from the group consisting of SEQ ID NO: 3, 4, 5, 6, 7 and 17; and wherein a second polypeptide and a third polypeptide are selected from the group consisting of: a) a polypeptide having the amino acid sequence selected from the group consisting SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17; b) a human cystatin C; c) a human beta-2-microglobulin; d) a 7.7 kD homologue of human myoglobin; e) neurosecretory protein VGF; f) a fragment of at least 5 amino acids of human cystatin C; g) a fragment of at least 5 amino acids of human beta-2-microglobulin; h) a fragment of at least 5 amino acids of the 7.7 kD homologue of human myoglobin; and i) a fragment of at least 5 amino acids of neurosecretory protein VGF. ### Claim 10 (depends on 9) The method of claim 9, wherein the method further comprises contacting the sample with an antibody that specifically binds one of the polypeptides. ### Claim 11 (depends on 9) The method of claim 9, wherein at least one polypeptide is detected by SELDI-TOF MS. ### Claim 12 (depends on 9) The method of claim 9, wherein the method is performed on at least two samples from the subject. ### Claim 13 (depends on 9) The method of claim 9, wherein the sample is CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, or cell extract. ### Claim 14 (depends on 9) The method of claim 9, wherein the polypeptides are detected in one sample from the subject. ### Claim 15 (depends on 9) The method of claim 9, wherein the method comprises detecting at least four distinct polypeptides, wherein a fourth polypeptide is selected from the group consisting of: a) a polypeptide having the amino acid sequence selected from the group consisting SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17; b) a human cystatin C; c) a human beta-2-microglobulin; d) a 7.7 kD homologue of human myoglobin; e) neurosecretory protein VGF; f) a fragment of at least 5 amino acids of human cystatin C; g) a fragment of at least 5 amino acids of human beta-2-microglobulin; h) a fragment of at least 5 amino acids of the 7.7 kD homologue of human myoglobin; and i) a fragment of at least 5 amino acids of neurosecretory protein VGF. ### Claim 16 (depends on 15) The method of claim 15, wherein the polypeptides are detected in one sample from the subject. ### Claim 17 (depends on 15) The method of claim 15, wherein the method comprises detecting at least five distinct polypeptides, wherein a fifth polypeptide is selected from the group consisting of: a) a polypeptide having the amino acid sequence selected from the group consisting SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17; b) a human cystatin C; c) a human beta-2-microglobulin; d) a 7.7 kD homologue of human myoglobin; e) neurosecretory protein VGF; f) a fragment of at least 5 amino acids of human cystatin C; g) a fragment of at least 5 amino acids of human beta-2-microglobulin; h) a fragment of at least 5 amino acids of the 7.7 kD homologue of human myoglobin; and i) a fragment of at least 5 amino acids of neurosecretory protein VGF. ### Claim 18 (depends on 17) The method of claim 17, wherein the polypeptides are detected in one sample from the subject.